Drug Profile
Research programme: inflammasome inhibitors - Jecure Therapeutics
Alternative Names: JT 194; JT 349Latest Information Update: 28 Mar 2022
Price :
$50
*
At a glance
- Originator Jecure Therapeutics
- Class Hepatoprotectants; Small molecules
- Mechanism of Action Inflammasome inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Hepatic fibrosis; Non-alcoholic steatohepatitis
Most Recent Events
- 28 Mar 2022 No recent reports of development identified for preclinical development in Hepatic-fibrosis in USA (PO)
- 28 Mar 2022 No recent reports of development identified for preclinical development in Non-alcoholic-steatohepatitis in USA (PO)
- 28 Feb 2018 Preclinical trials in Hepatic fibrosis in USA (PO)